In 2005, Anisimov and colleagues demonstrated that metformin treatment (1200 mg/L, equivalent to 240 mg/kg body weight) from 2 months of age until natural death in transgenic FVB/N female mice carrying the HER-2/neu mammary cancer gene improved lifespan by approximately 8% [31]. This evidence concerns the gene ERBB2 and breast cancer.